The Insulin Resistance Intervention after Stroke (IRIS) trial which involved 3876 patients, demonstrated that pioglitazone, an insulin-sensitizer, reduced the risk of recurrent stroke and myocardial infarction in patients without diabetes who had recent ischemic stroke or TIA11. This evidence concerns the gene INS and Stroke.